MFGE8 and cancer: Consistently, in comparison with normal counterparts, the splicing of MFGE8 is shifted towards a reduced proportion of MFGE8-L across multiple cancer types, including LUAD, HNSC, COAD, etc (Figure 7—figure supplement 1A).